Group 1 - The rapid rise of the innovative drug sector has created opportunities for many pharmaceutical-themed funds currently in fundraising [1] - Several newly launched pharmaceutical funds have chosen to close fundraising early to seize the market window [1] - The performance of the innovative drug sector has led to significant increases in the stock prices of preferred pharmaceutical holdings, with some rising between 20% to 30% in just five trading days [3] Group 2 - Fund companies are increasingly focusing on the purchase experience of fund holders, especially for new fund products [2] - There has been a trend of mini funds experiencing significant growth in scale after strong performance, while larger initial scale funds have faced redemptions due to poor performance [2] - The innovative drug sector is transitioning from losses to profitability, with a critical period for profitability expected between 2025 and 2028 [3]
创新药行情如火如荼 多只医药基金提前结募
Zheng Quan Shi Bao·2025-06-11 17:29